New drug combo shows promise for controlling advanced breast cancer

NCT ID NCT02668666

First seen Jan 27, 2026 · Last updated May 13, 2026 · Updated 11 times

Summary

This study tested a combination of two drugs, palbociclib and tamoxifen, as the first treatment for people with a certain type of advanced breast cancer (hormone receptor positive, HER2 negative). The goal was to see how long the cancer could be kept from growing. 49 participants took part. The approach aims to control the disease, not cure it, and patients may need ongoing treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Michigan State University

    Lansing, Michigan, 48910, United States

  • Penn State Cancer Institute

    Hershey, Pennsylvania, 17033, United States

  • ProHealth Care

    Waukesha, Wisconsin, 53188, United States

  • University of Illinois Cancer Center

    Chicago, Illinois, 60612, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

  • University of Wisconsin

    Madison, Wisconsin, 53705, United States

Conditions

Explore the condition pages connected to this study.